Loading...

Gregory Light

TitleProfessor In Residence
InstitutionUniversity of California San Diego
DepartmentPsychiatry
Address9500 Gilman Drive #0804
La Jolla CA 92093
Phone619-543-2496
vCardDownload vCard
    Other Positions
    TitleDeputy Vice Chair, Psychiatry Education and Training


    Collapse Overview 
    Collapse Overview
    Dr. Gregory Light is a Professor and Deputy Vice Chair of Education and Training in the UCSD Department of Psychiatry. Dr. Light also serves as the Director of Mental Health Research and the Director of the Mental Illness, Research, Education and Clinical Center (MIRECC) at the VA San Diego Healthcare System. In these roles, he provide leadership, supervision, and administrative support across several clinical, education, and multidisciplinary research programs. Dr. Light has published over 120 peer-reviewed papers (h-index=49). This work has been prominently featured in policy reports from the Institute of Medicine for next-generation strategies for personalized treatments of psychotic disorders.

    Psychotic disorders have devastating and often life-long consequences for approximately 2% of the global population. Most psychiatric interventions are implemented in the absence of knowledge about individual variation in important domains of brain function that might influence therapeutic response and outcome. This “one-size-fits-all” approach to treatment is problematic, with treatment failure occurring far too often and incurring substantial cost to the patient, family, therapist and larger social system. To “bend the curve” on the individual outcomes and societal impact of chronic psychotic illness, we must advance our understanding of the neural substrates of the illness features that most strongly contribute to poor outcomes, and use this information to guide mechanistically informed, personalized treatments. My program of research has advanced the use of neurophysiological biomarkers to develop precision medicine trials for psychosis patients that are: 1) effectively delivered in “real-world” community centers; and 2) informed by objective, reliable, validated, and low-cost biomarkers for identifying patients most likely to benefit (or not) from treatments. Findings support large-scale biomarker-guided trials to prevent or ameliorate illness in high-risk cohorts or treatment refractory populations. This program ultimately aims to develop and apply personalized biomarker assessment tools to deliver the “right treatment” to the “right person” at the “right time.”

    Dr. Light's career has maintained a focus on developing scientists for careers in academic medicine and neuroscience. As Deputy Vice Chair of Psychiatry Education and Training in the UCSD Department of Psychiatry, Dr.Light assists in the oversight of over 25 Programs. As Center Director of the Mental Illness, Research, Education, and Clinical Center (MIRECC) at the VA San Diego Healthcare System, he oversees 2 successful post-doctoral fellowship programs and coordinates the activities of trainees at many levels. Dr. Light also provides frequent lectures and serves on independent study, thesis, and dissertation committees across departments at UCSD including: Psychiatry, Psychology, Neuroscience, Cognitive Science, and Biology. Dr. Light also oversees medical student research studies. I serve as a mentor for 3 prominent international neuropsychiatric research organizations: Society of Biological Psychiatry, the American College of Neuropsychopharmacology, and International Congress on Schizophrenia Research.


    Collapse Research 
    Collapse Research Activities and Funding
    Accelerated Inflammaging in Schizophrenia
    NIH/NIMH R01MH094151May 1, 2012 - Feb 28, 2022
    Role: Principal Investigator
    Pathway(s) From Genes to Functional Deficits of Schizophrenia Patients
    NIH/NIMH R01MH079777Jul 25, 2007 - May 31, 2013
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Websites
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Thomas ML, Bismark AW, Joshi YB, Tarasenko M, Treichler EBH, Hochberger WC, Zhang W, Nungaray J, Sprock J, Cardoso L, Tiernan K, Attarha M, Braff DL, Vinogradov S, Swerdlow N, Light GA. Targeted cognitive training improves auditory and verbal outcomes among treatment refractory schizophrenia patients mandated to residential care. Schizophr Res. 2018 Jul 25. PMID: 30055883.
      View in: PubMed
    2. Thomas ML, Treichler EBH, Bismark A, Shiluk AL, Tarasenko M, Zhang W, Joshi YB, Sprock J, Cardoso L, Tiernan K, Light GA. Computerized cognitive training is associated with improved psychosocial treatment engagement in schizophrenia. Schizophr Res. 2018 Jun 18. PMID: 29929773.
      View in: PubMed
    3. Bismark AW, Thomas ML, Tarasenko M, Shiluk AL, Rackelmann SY, Young JW, Light GA. Reverse translated and gold standard continuous performance tests predict global cognitive performance in schizophrenia. Transl Psychiatry. 2018 Apr 12; 8(1):80. PMID: 29643355.
      View in: PubMed
    4. Swerdlow NR, Bhakta SG, Light GA. Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge. Schizophr Res. 2018 Apr 04. PMID: 29627173.
      View in: PubMed
    5. Swerdlow NR, Light GA. Sensorimotor gating deficits in schizophrenia: Advancing our understanding of the phenotype, its neural circuitry and genetic substrates. Schizophr Res. 2018 Mar 07. PMID: 29525460.
      View in: PubMed
    6. Young JW, Light GA. Cross-Species Neurophysiological Biomarkers of Attentional Dysfunction in Schizophrenia: Bridging the Translational Gap. Neuropsychopharmacology. 2018 Jan; 43(1):230-231. PMID: 29192660.
      View in: PubMed
    7. Pospos S, Young IT, Downs N, Iglewicz A, Depp C, Chen JY, Newton I, Lee K, Light GA, Zisook S. Web-Based Tools and Mobile Applications To Mitigate Burnout, Depression, and Suicidality Among Healthcare Students and Professionals: a Systematic Review. Acad Psychiatry. 2018 Feb; 42(1):109-120. PMID: 29256033.
      View in: PubMed
    8. Bhakta SG, Light GA, Talledo JA, Balvaneda B, Hughes E, Alvarez A, Rana BK, Young JW, Swerdlow NR. Tolcapone-Enhanced Neurocognition in Healthy Adults: Neural Basis and Predictors. Int J Neuropsychopharmacol. 2017 12 01; 20(12):979-987. PMID: 29020372.
      View in: PubMed
    9. Swerdlow NR, Bhakta SG, Talledo JA, Franz DM, Hughes EL, Rana BK, Light GA. Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients. Neuropsychopharmacology. 2018 Mar; 43(4):708-717. PMID: 29154367.
      View in: PubMed
    10. Joshi YB, Breitenstein B, Tarasenko M, Thomas ML, Chang WL, Sprock J, Sharp RF, Light GA. Mismatch negativity impairment is associated with deficits in identifying real-world environmental sounds in schizophrenia. Schizophr Res. 2018 Jan; 191:5-9. PMID: 28927552.
      View in: PubMed
    11. Swerdlow NR, Tarasenko M, Bhakta SG, Talledo J, Alvarez AI, Hughes EL, Rana B, Vinogradov S, Light GA. Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients. Schizophr Bull. 2017 Jul 01; 43(4):872-880. PMID: 27798224.
      View in: PubMed
    12. Bismark AW, Thomas ML, Tarasenko M, Shiluk AL, Rackelmann SY, Young JW, Light GA. Relationship between effortful motivation and neurocognition in schizophrenia. Schizophr Res. 2018 Mar; 193:69-76. PMID: 28673753.
      View in: PubMed
    13. Swerdlow NR, Light GA, Thomas ML, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Deficient prepulse inhibition in schizophrenia in a multi-site cohort: Internal replication and extension. Schizophr Res. 2017 May 23. PMID: 28549722.
      View in: PubMed
    14. Light GA, Zhang W, Joshi YB, Bhakta S, Talledo JA, Swerdlow NR. Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia. Neuropsychopharmacology. 2017 Dec; 42(13):2633-2639. PMID: 28425497.
      View in: PubMed
    15. Thomas ML, Patt VM, Bismark A, Sprock J, Tarasenko M, Light GA, Brown GG. Evidence of systematic attenuation in the measurement of cognitive deficits in schizophrenia. J Abnorm Psychol. 2017 Apr; 126(3):312-324. PMID: 28277736.
      View in: PubMed
    16. Perez VB, Tarasenko M, Miyakoshi M, Pianka ST, Makeig SD, Braff DL, Swerdlow NR, Light GA. Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia. Neuropsychopharmacology. 2017 Oct; 42(11):2206-2213. PMID: 28139679.
      View in: PubMed
    17. Thomas ML, Green MF, Hellemann G, Sugar CA, Tarasenko M, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Shiluk AL, Siever LJ, Silverman JM, Sprock J, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL, Light GA. Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. JAMA Psychiatry. 2017 Jan 01; 74(1):37-46. PMID: 27926742.
      View in: PubMed
    18. Young JW, Bismark AW, Sun Y, Zhang W, McIlwain M, Grootendorst I, Light GA. Neurophysiological Characterization of Attentional Performance Dysfunction in Schizophrenia Patients in a Reverse-Translated Task. Neuropsychopharmacology. 2017 May; 42(6):1338-1348. PMID: 27917869.
      View in: PubMed
    19. Millard SP, Shofer J, Braff D, Calkins M, Cadenhead K, Freedman R, Green MF, Greenwood TA, Gur R, Gur R, Lazzeroni LC, Light GA, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone WS, Sprock J, Sugar CA, Swerdlow NR, Tsuang M, Turetsky B, Radant A, Tsuang DW. Prioritizing schizophrenia endophenotypes for future genetic studies: An example using data from the COGS-1 family study. Schizophr Res. 2016 07; 174(1-3):1-9. PMID: 27132484; PMCID: PMC4912929 [Available on 07/01/17].
    20. Bhakta SG, Chou HH, Rana B, Talledo JA, Balvaneda B, Gaddis L, Light GA, Swerdlow NR. Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy. Psychopharmacology (Berl). 2016 06; 233(12):2399-410. PMID: 27076209.
      View in: PubMed
    21. Tarasenko M, Perez VB, Pianka ST, Vinogradov S, Braff DL, Swerdlow NR, Light GA. Measuring the capacity for auditory system plasticity: An examination of performance gains during initial exposure to auditory-targeted cognitive training in schizophrenia. Schizophr Res. 2016 Apr; 172(1-3):123-30. PMID: 26851143.
      View in: PubMed
    22. Swerdlow NR, Light GA. Animal Models of Deficient Sensorimotor Gating in Schizophrenia: Are They Still Relevant? Curr Top Behav Neurosci. 2016; 28:305-25. PMID: 27311762.
      View in: PubMed
    23. Greenwood TA, Lazzeroni LC, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study. Schizophr Res. 2016 Jan; 170(1):30-40. PMID: 26597662; PMCID: PMC4707095 [Available on 01/01/17].
    24. Greenwood TA, Light GA, Swerdlow NR, Calkins ME, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL. Gating Deficit Heritability and Correlation With Increased Clinical Severity in Schizophrenia Patients With Positive Family History. Am J Psychiatry. 2016 Apr 01; 173(4):385-91. PMID: 26441157; PMCID: PMC4933520 [Available on 04/01/17].
    25. Swerdlow NR, Bhakta S, Chou HH, Talledo JA, Balvaneda B, Light GA. Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis. Neuropsychopharmacology. 2016 Jan; 41(2):419-30. PMID: 26062785.
      View in: PubMed
    26. Light GA, Swerdlow NR. Bending the curve on psychosis outcomes. Lancet Psychiatry. 2015 May; 2(5):365-367. PMID: 26360262.
      View in: PubMed
    27. Young JW, Kamenski ME, Higa KK, Light GA, Geyer MA, Zhou X. GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders. Neuropsychopharmacology. 2015 Nov; 40(12):2715-26. PMID: 25907107; PMCID: PMC4864647 [Available on 11/01/16].
    28. Gur RC, Braff DL, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Gur RE. Neurocognitive performance in family-based and case-control studies of schizophrenia. Schizophr Res. 2015 Apr; 163(1-3):17-23. PMID: 25432636; PMCID: PMC4441547.
    29. Light GA, Swerdlow NR. Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia. Ann N Y Acad Sci. 2015 May; 1344:105-19. PMID: 25752648; PMCID: PMC4412775.
    30. Nuechterlein KH, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2015 Apr; 163(1-3):38-46. PMID: 25749017; PMCID: PMC4382444.
    31. Seidman LJ, Hellemann G, Nuechterlein KH, Greenwood TA, Braff DL, Cadenhead KS, Calkins ME, Freedman R, Gur RE, Gur RC, Lazzeroni LC, Light GA, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar C, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. Factor structure and heritability of endophenotypes in schizophrenia: findings from the Consortium on the Genetics of Schizophrenia (COGS-1). Schizophr Res. 2015 Apr; 163(1-3):73-9. PMID: 25682549.
      View in: PubMed
    32. Light GA, Makeig S. Electroencephalographic biomarkers of psychosis: present and future. Biol Psychiatry. 2015 Jan 15; 77(2):87-9. PMID: 25524305.
      View in: PubMed
    33. Radant AD, Millard SP, Braff DL, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Meichle SP, Nuechterlein KH, Olincy A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Sugar CA, Tsuang MT, Turetsky BI, Tsuang DW. Robust differences in antisaccade performance exist between COGS schizophrenia cases and controls regardless of recruitment strategies. Schizophr Res. 2015 Apr; 163(1-3):47-52. PMID: 25553977; PMCID: PMC4382408.
    34. Stone WS, Mesholam-Gately RI, Braff DL, Calkins ME, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Seidman LJ. California Verbal Learning Test-II performance in schizophrenia as a function of ascertainment strategy: comparing the first and second phases of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2015 Apr; 163(1-3):32-7. PMID: 25497440.
      View in: PubMed
    35. Light GA, Swerdlow NR, Thomas ML, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Pela M, Radant AD, Seidman LJ, Sharp RF, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Braff DL, Turetsky BI. Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2. Schizophr Res. 2015 Apr; 163(1-3):63-72. PMID: 25449710; PMCID: PMC4382452.
    36. Tarasenko MA, Swerdlow NR, Makeig S, Braff DL, Light GA. The auditory brain-stem response to complex sounds: a potential biomarker for guiding treatment of psychosis. Front Psychiatry. 2014; 5:142. PMID: 25352811; PMCID: PMC4195270.
    37. Turetsky BI, Dress EM, Braff DL, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Light G. The utility of P300 as a schizophrenia endophenotype and predictive biomarker: clinical and socio-demographic modulators in COGS-2. Schizophr Res. 2015 Apr; 163(1-3):53-62. PMID: 25306203; PMCID: PMC4382423.
    38. Rissling AJ, Miyakoshi M, Sugar CA, Braff DL, Makeig S, Light GA. Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia. Neuroimage Clin. 2014; 6:424-37. PMID: 25379456.
      View in: PubMed
    39. Lee J, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) study: the moderating role of smoking status and antipsychotic medications. Schizophr Res. 2015 Apr; 163(1-3):24-31. PMID: 25248939; PMCID: PMC4368500.
    40. Light G, Greenwood TA, Swerdlow NR, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Comparison of the heritability of schizophrenia and endophenotypes in the COGS-1 family study. Schizophr Bull. 2014 Nov; 40(6):1404-11. PMID: 24903414; PMCID: PMC4193725.
    41. Schmeidler J, Lazzeroni LC, Swerdlow NR, Ferreira RP, Braff DL, Calkins ME, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Olincy A, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Stone WS, Sprock J, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Silverman JM. Paternal age of schizophrenia probands and endophenotypic differences from unaffected siblings. Psychiatry Res. 2014 Sep 30; 219(1):67-71. PMID: 24913833; PMCID: PMC4110721.
    42. Mano QR, Brown GG, Mirzakhanian H, Bolden K, Cadenhead KS, Light GA. Not all distraction is bad: working memory vulnerability to implicit socioemotional distraction correlates with negative symptoms and functional impairment in psychosis. Schizophr Res Treatment. 2014; 2014:320948. PMID: 24724026; PMCID: PMC3958678.
    43. Tsuang D, Esterberg M, Braff D, Calkins M, Cadenhead K, Dobie D, Freedman R, Green MF, Greenwood T, Gur R, Gur R, Horan W, Lazzeroni LC, Light GA, Millard SP, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone W, Sprock J, Sugar C, Swerdlow N, Tsuang M, Turetsky B, Radant A. Is there an association between advanced paternal age and endophenotype deficit levels in schizophrenia? PLoS One. 2014; 9(2):e88379. PMID: 24523888; PMCID: PMC3921166.
    44. Swerdlow NR, Light GA, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Ray A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophr Res. 2014 Feb; 152(2-3):503-12. PMID: 24405980; PMCID: PMC3960985.
    45. Perez VB, Swerdlow NR, Braff DL, Näätänen R, Light GA. Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses. Biomark Med. 2014; 8(1):9-14. PMID: 24325220; PMCID: PMC4043396.
    46. Light GA, Swerdlow NR. Neurophysiological biomarkers informing the clinical neuroscience of schizophrenia: mismatch negativity and prepulse inhibition of startle. Curr Top Behav Neurosci. 2014; 21:293-314. PMID: 24850080.
      View in: PubMed
    47. Young JW, Geyer MA, Rissling AJ, Sharp RF, Eyler LT, Asgaard GL, Light GA. Reverse translation of the rodent 5C-CPT reveals that the impaired attention of people with schizophrenia is similar to scopolamine-induced deficits in mice. Transl Psychiatry. 2013 Nov 12; 3:e324. PMID: 24217494.
      View in: PubMed
    48. Swerdlow NR, Light GA, Trim RS, Breier MR, Hines SR, Powell SB. Forebrain gene expression predicts deficits in sensorimotor gating after isolation rearing in male rats. Behav Brain Res. 2013 Nov 15; 257:118-28. PMID: 24076151; PMCID: PMC3897308.
    49. Light GA, Näätänen R. Mismatch negativity is a breakthrough biomarker for understanding and treating psychotic disorders. Proc Natl Acad Sci U S A. 2013 Sep 17; 110(38):15175-6. PMID: 23995447; PMCID: PMC3780842.
    50. Cadenhead KS, Addington J, Cannon TD, Cornblatt BA, de la Fuente-Sandoval C, Mathalon DH, Perkins DO, Seidman LJ, Tsuang M, Walker EF, Woods SW, Bachman P, Belger A, Carrión RE, Donkers FC, Duncan E, Johannesen J, León-Ortiz P, Light G, Mondragón A, Niznikiewicz M, Nunag J, Roach BJ, Solís-Vivanco R. Between-site reliability of startle prepulse inhibition across two early psychosis consortia. Neuroreport. 2013 Aug 07; 24(11):626-30. PMID: 23799460; PMCID: PMC4135529.
    51. Swerdlow NR, Powell SB, Breier MR, Hines SR, Light GA. Coupling of gene expression in medial prefrontal cortex and nucleus accumbens after neonatal ventral hippocampal lesions accompanies deficits in sensorimotor gating and auditory processing in rats. Neuropharmacology. 2013 Dec; 75:38-46. PMID: 23810830; PMCID: PMC3825835.
    52. Greenwood TA, Swerdlow NR, Gur RE, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Ray A, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Light GA, Braff DL. Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2013 May; 170(5):521-32. PMID: 23511790; PMCID: PMC3878873.
    53. Rissling AJ, Park SH, Young JW, Rissling MB, Sugar CA, Sprock J, Mathias DJ, Pela M, Sharp RF, Braff DL, Light GA. Demand and modality of directed attention modulate "pre-attentive" sensory processes in schizophrenia patients and nonpsychiatric controls. Schizophr Res. 2013 May; 146(1-3):326-35. PMID: 23490760.
      View in: PubMed
    54. Calkins ME, Ray A, Gur RC, Freedman R, Green MF, Greenwood TA, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar C, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL, Lazzeroni LC, Gur RE. Sex differences in familiality effects on neurocognitive performance in schizophrenia. Biol Psychiatry. 2013 May 15; 73(10):976-84. PMID: 23395246; PMCID: PMC3954126.
    55. Takahashi H, Rissling AJ, Pascual-Marqui R, Kirihara K, Pela M, Sprock J, Braff DL, Light GA. Neural substrates of normal and impaired preattentive sensory discrimination in large cohorts of nonpsychiatric subjects and schizophrenia patients as indexed by MMN and P3a change detection responses. Neuroimage. 2013 Feb 01; 66:594-603. PMID: 23085112; PMCID: PMC3652903.
    56. Light GA, Swerdlow NR, Rissling AJ, Radant A, Sugar CA, Sprock J, Pela M, Geyer MA, Braff DL. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One. 2012; 7(7):e39434. PMID: 22802938.
      View in: PubMed
    57. Swerdlow NR, Shilling PD, Breier M, Trim RS, Light GA, Marie RS. Fronto-temporal-mesolimbic gene expression and heritable differences in amphetamine-disrupted sensorimotor gating in rats. Psychopharmacology (Berl). 2012 Dec; 224(3):349-62. PMID: 22700037.
      View in: PubMed
    58. Rissling AJ, Braff DL, Swerdlow NR, Hellemann G, Rassovsky Y, Sprock J, Pela M, Light GA. Disentangling early sensory information processing deficits in schizophrenia. Clin Neurophysiol. 2012 Oct; 123(10):1942-9. PMID: 22608970; PMCID: PMC3436955.
    59. Swerdlow NR, Light GA, Breier MR, Shoemaker JM, Saint Marie RL, Neary AC, Geyer MA, Stevens KE, Powell SB. Sensory and sensorimotor gating deficits after neonatal ventral hippocampal lesions in rats. Dev Neurosci. 2012; 34(2-3):240-9. PMID: 22572564.
      View in: PubMed
    60. Thorp SR, Sones HM, Glorioso D, Thompson W, Light GA, Golshan S, Jeste DV. Older patients with schizophrenia: does military veteran status matter? Am J Geriatr Psychiatry. 2012 Mar; 20(3):248-56. PMID: 22354115; PMCID: PMC3286234.
    61. Kirihara K, Rissling AJ, Swerdlow NR, Braff DL, Light GA. Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia. Biol Psychiatry. 2012 May 15; 71(10):873-80. PMID: 22361076.
      View in: PubMed
    62. Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff DL. Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS One. 2012; 7(1):e29630. PMID: 22253750; PMCID: PMC3258248.
    63. Sun Y, Farzan F, Barr MS, Kirihara K, Fitzgerald PB, Light GA, Daskalakis ZJ. ? oscillations in schizophrenia: mechanisms and clinical significance. Brain Res. 2011 Sep 21; 1413:98-114. PMID: 21840506.
      View in: PubMed
    64. Jahshan C, Cadenhead KS, Rissling AJ, Kirihara K, Braff DL, Light GA. Automatic sensory information processing abnormalities across the illness course of schizophrenia. Psychol Med. 2012 Jan; 42(1):85-97. PMID: 21740622.
      View in: PubMed
    65. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Gur RE, Gur RC, Hardiman G, Kelsoe JR, Leonard S, Light GA, Nuechterlein KH, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2011 Sep; 168(9):930-46. PMID: 21498463; PMCID: PMC3751972.
    66. Stone WS, Giuliano AJ, Tsuang MT, Braff DL, Cadenhead KS, Calkins ME, Dobie DJ, Faraone SV, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Roe AH, Schork NJ, Siever LJ, Silverman JM, Swerdlow NR, Thomas AR, Tsuang DW, Turetsky BI, Seidman LJ. Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2011 May; 128(1-3):102-10. PMID: 21288694.
      View in: PubMed
    67. Rissling AJ, Makeig S, Braff DL, Light GA. Neurophysiologic markers of abnormal brain activity in schizophrenia. Curr Psychiatry Rep. 2010 Dec; 12(6):572-8. PMID: 20857348; PMCID: PMC2965365.
    68. Williams LE, Ramachandran VS, Hubbard EM, Braff DL, Light GA. Superior size-weight illusion performance in patients with schizophrenia: evidence for deficits in forward models. Schizophr Res. 2010 Aug; 121(1-3):101-6. PMID: 19931421; PMCID: PMC2910228.
    69. Light GA, Williams LE, Minow F, Sprock J, Rissling A, Sharp R, Swerdlow NR, Braff DL. Electroencephalography (EEG) and event-related potentials (ERPs) with human participants. Curr Protoc Neurosci. 2010 Jul; Chapter 6:Unit 6.25.1-24. PMID: 20578033.
      View in: PubMed
    70. Williams LE, Light GA, Braff DL, Ramachandran VS. Reduced multisensory integration in patients with schizophrenia on a target detection task. Neuropsychologia. 2010 Aug; 48(10):3128-36. PMID: 20600181; PMCID: PMC2915827.
    71. Olincy A, Braff DL, Adler LE, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Wagner BD, Freedman R. Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia. Schizophr Res. 2010 Jun; 119(1-3):175-82. PMID: 20382002; PMCID: PMC3688282.
    72. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Meichle SP, Millard SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: data from the COGS study. Psychophysiology. 2010 Sep; 47(5):846-56. PMID: 20374545; PMCID: PMC4176871.
    73. Breier MR, Lewis B, Shoemaker JM, Light GA, Swerdlow NR. Sensory and sensorimotor gating-disruptive effects of apomorphine in Sprague Dawley and Long Evans rats. Behav Brain Res. 2010 Apr 02; 208(2):560-5. PMID: 20080128; PMCID: PMC2834557.
    74. Rissling AJ, Light GA. Neurophysiological measures of sensory registration, stimulus discrimination, and selection in schizophrenia patients. Curr Top Behav Neurosci. 2010; 4:283-309. PMID: 21312404.
      View in: PubMed
    75. Kiang M, Braff DL, Sprock J, Light GA. The relationship between preattentive sensory processing deficits and age in schizophrenia patients. Clin Neurophysiol. 2009 Nov; 120(11):1949-57. PMID: 19786365; PMCID: PMC2902236.
    76. Young JW, Light GA, Marston HM, Sharp R, Geyer MA. The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One. 2009; 4(1):e4227. PMID: 19156216; PMCID: PMC2626630.
    77. Turetsky BI, Greenwood TA, Olincy A, Radant AD, Braff DL, Cadenhead KS, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Calkins ME. Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol Psychiatry. 2008 Dec 15; 64(12):1051-9. PMID: 18701089; PMCID: PMC2653714.
    78. Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl). 2008 Aug; 199(3):331-88. PMID: 18568339; PMCID: PMC2771731.
    79. Horan WP, Braff DL, Nuechterlein KH, Sugar CA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2008 Aug; 103(1-3):218-28. PMID: 18406578; PMCID: PMC2529172.
    80. Braff DL, Greenwood TA, Swerdlow NR, Light GA, Schork NJ. Advances in endophenotyping schizophrenia. World Psychiatry. 2008 Feb; 7(1):11-8. PMID: 18458787; PMCID: PMC2359727.
    81. Kiang M, Kutas M, Light GA, Braff DL. An event-related brain potential study of direct and indirect semantic priming in schizophrenia. Am J Psychiatry. 2008 Jan; 165(1):74-81. PMID: 18056222.
      View in: PubMed
    82. Greenwood TA, Braff DL, Light GA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Schork NJ. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry. 2007 Nov; 64(11):1242-50. PMID: 17984393.
      View in: PubMed
    83. Light GA, Swerdlow NR, Braff DL. Preattentive sensory processing as indexed by the MMN and P3a brain responses is associated with cognitive and psychosocial functioning in healthy adults. J Cogn Neurosci. 2007 Oct; 19(10):1624-32. PMID: 18271737; PMCID: PMC2562660.
    84. Möller B, Light GA, Fitzgerald PB, Snyder JS, Chen R, Daskalakis ZJ. Relationship between P50 suppression and the cortical silent period. Neuroreport. 2007 Sep 17; 18(14):1503-6. PMID: 17712283.
      View in: PubMed
    85. Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C, Erhart S, Marder SR, Mintz J, Braff DL. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res. 2007 Sep; 95(1-3):134-42. PMID: 17662577; PMCID: PMC2716219.
    86. Kiang M, Light GA, Prugh J, Coulson S, Braff DL, Kutas M. Cognitive, neurophysiological, and functional correlates of proverb interpretation abnormalities in schizophrenia. J Int Neuropsychol Soc. 2007 Jul; 13(4):653-63. PMID: 17521483.
      View in: PubMed
    87. Kiang M, Kutas M, Light GA, Braff DL. Electrophysiological insights into conceptual disorganization in schizophrenia. Schizophr Res. 2007 May; 92(1-3):225-36. PMID: 17383161; PMCID: PMC3974604.
    88. Swerdlow NR, Sprock J, Light GA, Cadenhead K, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Mintz J, Olincy A, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2007 May; 92(1-3):237-51. PMID: 17346930; PMCID: PMC2039885.
    89. Braff DL, Light GA, Swerdlow NR. Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry. 2007 May 15; 61(10):1204-7. PMID: 17161386.
      View in: PubMed
    90. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry. 2006 Dec; 63(12):1325-35. PMID: 17146007.
      View in: PubMed
    91. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull. 2007 Jan; 33(1):69-94. PMID: 17135482; PMCID: PMC2632291.
    92. Calkins ME, Dobie DJ, Cadenhead KS, Olincy A, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull. 2007 Jan; 33(1):33-48. PMID: 17035358; PMCID: PMC2632302.
    93. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Light GA, Meichle SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res. 2007 Jan; 89(1-3):320-9. PMID: 17023145.
      View in: PubMed
    94. Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR, Braff DL. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry. 2006 Dec 01; 60(11):1231-40. PMID: 16893524.
      View in: PubMed
    95. Swerdlow NR, Geyer MA, Shoemaker JM, Light GA, Braff DL, Stevens KE, Sharp R, Breier M, Neary A, Auerbach PP. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology. 2006 Mar; 31(3):506-15. PMID: 16123772; PMCID: PMC1373667.
    96. Wynn JK, Light GA, Breitmeyer B, Nuechterlein KH, Green MF. Event-related gamma activity in schizophrenia patients during a visual backward-masking task. Am J Psychiatry. 2005 Dec; 162(12):2330-6. PMID: 16330598.
      View in: PubMed
    97. Light GA, Braff DL. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am J Psychiatry. 2005 Sep; 162(9):1741-3. PMID: 16135637.
      View in: PubMed
    98. Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, Light GA. Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol. 2005 Jul-Aug; 28(4):179-84. PMID: 16062097.
      View in: PubMed
    99. Cadenhead KS, Light GA, Shafer KM, Braff DL. P50 suppression in individuals at risk for schizophrenia: the convergence of clinical, familial, and vulnerability marker risk assessment. Biol Psychiatry. 2005 Jun 15; 57(12):1504-9. PMID: 15953486.
      View in: PubMed
    100. Meincke U, Light GA, Geyer MA, Braff DL. On the waveform of the acoustic startle blink in the paradigm of prepulse inhibition - methodological and physiological aspects. Neuropsychobiology. 2005; 52(1):24-7. PMID: 15942260.
      View in: PubMed
    101. Swerdlow NR, Stephany NL, Talledo J, Light G, Braff DL, Baeyens D, Auerbach PP. Prepulse inhibition of perceived stimulus intensity: paradigm assessment. Biol Psychol. 2005 May; 69(2):133-47. PMID: 15804542.
      View in: PubMed
    102. Braff DL, Light GA, Ellwanger J, Sprock J, Swerdlow NR. Female schizophrenia patients have prepulse inhibition deficits. Biol Psychiatry. 2005 Apr 01; 57(7):817-20. PMID: 15820241.
      View in: PubMed
    103. Light GA, Braff DL. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry. 2005 Feb; 62(2):127-36. PMID: 15699289.
      View in: PubMed
    104. Braff DL, Light GA. The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin Neurosci. 2005; 7(2):125-35. PMID: 16262208; PMCID: PMC3181726.
    105. Braff DL, Light GA. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology (Berl). 2004 Jun; 174(1):75-85. PMID: 15118804.
      View in: PubMed
    106. Meincke U, Light GA, Geyer MA, Braff DL, Gouzoulis-Mayfrank E. Sensitization and habituation of the acoustic startle reflex in patients with schizophrenia. Psychiatry Res. 2004 Apr 15; 126(1):51-61. PMID: 15081627.
      View in: PubMed
    107. Green MF, Mintz J, Salveson D, Nuechterlein KH, Breitmeyer B, Light GA, Braff DL. Visual masking as a probe for abnormal gamma range activity in schizophrenia. Biol Psychiatry. 2003 Jun 15; 53(12):1113-9. PMID: 12814862.
      View in: PubMed
    108. Cadenhead KS, Light GA, Geyer MA, McDowell JE, Braff DL. Neurobiological measures of schizotypal personality disorder: defining an inhibitory endophenotype? Am J Psychiatry. 2002 May; 159(5):869-71. PMID: 11986147.
      View in: PubMed
    109. Light GA, Braff DL. Measuring P50 suppression and prepulse inhibition in a single recording session. Am J Psychiatry. 2001 Dec; 158(12):2066-8. PMID: 11729028.
      View in: PubMed
    110. Braff DL, Geyer MA, Light GA, Sprock J, Perry W, Cadenhead KS, Swerdlow NR. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res. 2001 Apr 15; 49(1-2):171-8. PMID: 11343875.
      View in: PubMed
    111. Perry W, Light GA, Davis H, Braff DL. Schizophrenia patients demonstrate a dissociation on declarative and non-declarative memory tests. Schizophr Res. 2000 Dec 15; 46(2-3):167-74. PMID: 11120428.
      View in: PubMed
    112. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry. 2000 May; 157(5):767-71. PMID: 10784470.
      View in: PubMed
    113. Light GA, Braff DL. Do self-reports of perceptual anomalies reflect gating deficits in schizophrenia patients? Biol Psychiatry. 2000 Mar 01; 47(5):463-7. PMID: 10704957.
      View in: PubMed
    114. Cadenhead KS, Light GA, Geyer MA, Braff DL. Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. Am J Psychiatry. 2000 Jan; 157(1):55-9. PMID: 10618013.
      View in: PubMed
    115. Light GA, Braff DL. Human and animal studies of schizophrenia-related gating deficits. Curr Psychiatry Rep. 1999 Oct; 1(1):31-40. PMID: 11122903.
      View in: PubMed
    116. Light GA, Malaspina D, Geyer MA, Luber BM, Coleman EA, Sackeim HA, Braff DL. Amphetamine disrupts P50 suppression in normal subjects. Biol Psychiatry. 1999 Oct 01; 46(7):990-6. PMID: 10509182.
      View in: PubMed
    117. Light GA, Braff DL. The "incredible shrinking" P50 event-related potential. Biol Psychiatry. 1998 Jun 15; 43(12):918-20. PMID: 9627748.
      View in: PubMed